The care gap: Underuse of statin therapy in the elderly

International Journal of Clinical Practice

Volumn 58, Issue 8, 2004, Pages 777-785

  Gaw, Allan ^a  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

Age; Cholesterol; Coronary heart disease; Dementia; Statin; Undertreatment

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

AGED; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY RISK; DEATH; DISABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG USE; HEALTH STATUS; HUMAN; HYPERCHOLESTEROLEMIA; INDEPENDENCE; ISCHEMIC HEART DISEASE; PATIENT CARE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE;

AGED; AGED, 80 AND OVER; ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COGNITION DISORDERS; HEALTH SERVICES FOR THE AGED; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RISK FACTORS;

EID: 4544315284     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1368-5031.2004.00300.x     Document Type: Review

References (80)

1. Sans S, Kesteloot H, Kromhout D, on behalf of the Task Force. The burden of cardiovascular disease mortality in Europe. Eur Heart J 1997; 18: 1231-48.
2. Denke MA, Grundy SM. Hypercholesterolemia in elderly persons: resolving the treatment dilemma. Ann Intern Med 1990; 112: 780-92.
3. Wilson PW, Anderson KM, Harris T et al. Determinants of change in total cholesterol and HDL-C with age: the Framingham Study. J Gerontol 1994; 49: M252-M7.
4. Wood D, De Backer G, Faergeman O et al. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur Heart J 1998; 19: 1434-503.
5. Larkin M, Robert B. Championing a healthy view of ageing. Lancet 2001; 357: 48.
6. Department of Economic and Social Affairs Population Division. United Nations, NY 2001: ST/ESA/SER.A/207.
7. Grundy SM. Statin therapy in older persons: pertinent issues. Arch Intern Med 2002; 162: 1329-31.
8. Gaw A, Robertson M, Ford I, PROSPER Study Group. Framingham risk equations underestimate risk in older subjects. Circulation 2003; 108 (Suppl): IV-721.
9. Wilson PW, D'Agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
10. Kalache A, Aboderin I. Stroke: the global burden. Health Policy Plan 1995; 10: 1-21.
11. Davis PH, Dambrosia JM, Schoenberg BS et al. Risk factors for ischemic stroke: a prospective study in Rochester, Minnesota. Ann Neurol 1987; 22: 319-27.
12. Blauw GJ, Bollen EL, van Buchem MA, Westendorp RG. Dementia at old age: a clinical end-point of atherosclerotic disease. Eur Heart J 2001; 3 (Suppl N): N16-N9.
13. Kannel WB. Coronary heart disease risk factors in the elderly. Am J Geriatr Cardiol 2002; 11: 101-7.
14. Krumholz HM, Seeman TE, Merrill SS et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA 1994; 272: 1335-40.
15. Chyou PH, Eaker ED. Serum cholesterol concentrations and all-cause mortality in older people. Age Ageing 2000; 29: 69-74.
16. Simons LA, Simons J, Friedlander Y, McCallum J. Cholesterol and other lipids predict coronary heart disease and ischaemic stroke in the elderly, but only in those below 70 years. Atherosclerosis 2001; 159: 201-8.
17. Grundy SM, Cleeman JI, Rifkind BM, Kuller LH. Cholesterol lowering in the elderly population. Coordinating Committee of the National Cholesterol Education Program. Arch Intern Med 1999; 159: 1670-8.
18. Harris T, Cook EF, Kannel WB, Goldman L. Proportional hazards analysis of risk factors for coronary heart disease in individuals aged 65 or older. The Framingham Heart Study. J Am Geriatr Soc 1988; 36: 1023-8.
19. Benfante R, Reed D, Frank J. Do coronary heart disease risk factors measured in the elderly have the same predictive roles as in the middle aged. Comparisons of relative and attributable risks. Ann Epidemiol 1992; 2: 273-82.
20. Clarke R, Lewington S, Youngman L et al. Underestimation of the importance of blood pressure and cholesterol for coronary heart disease mortality in old age. Eur Heart J 2002; 23: 286-93.
21. Houterman S, Boshuizen HC, Verschuren WMM et al. Predicting cardiovascular risk in the elderly in different European countries. Eur Heart J 2002; 23: 294-300.
22. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
23. Jones PH, Davidson MH, Stein EA et al., for the STELLAR Study Group. Comparison of the efficacy and safety of rosuvasatin versus atorvastatin, simvastatin and pravastatin across doses (STELLAR trial). Am J Cardiol 2003; 93: 152-60.
24. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81: 582-7.
25. Rosenson RS. Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther 2003; 1: 495-505.
26. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
27. Shepherd J, Cobbe SM, Ford I et al., for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
28. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Eng J Med 1996; 335: 1001-9.
29. Downs JR, Clearfield M, Weis S et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22.
30. The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
31. Ballantyne C. Low-density lipoproteins and the risk for coronary artery disease. Am J Cardiol 1998; 82: 3Q-12Q.
32. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
33. Waters DD, Hsue PY. Low-density-lipoprotein cholesterol goals for patients with coronary disease: treating between the lines. Circulation 2001; 104: 2635-7.
34. Miettinen TA, Pyörälä K, Olsson AG et al. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris. Circulation 1997; 96: 4211-8.
35. Lewis SJ, Moye LA, Sacks FM et al. Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the cholesterol and recurrent events (CARE) trial. Ann Intern Med 1998; 129: 681-9.
36. Hunt D, Young P, Simes J et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients. Results from the LIPID trial. Ann Intern Med 2001; 134: 931-40.
37. Blasetto J, Stein E, Brown WV et al. Efficacy of rosuvastatin compared with other statins at selected starting doses in hyper-cholesterolemic patients and in special population groups. Am J Cardiol 2003; 91: 3C-10C.
38. Santanello NC, Barber BL, Applegate WB et al. Effect of pharmacologic lipid lowering on health-related quality of life in older persons: results from the Cholesterol Reduction In Seniors Program (CRISP) pilot study. J Am Geriatr Soc 1997; 45: 8-14.
39. Collins R, Peto R, Armitage J. The MRC/BHF Heart Protection Study: preliminary results. Int J Clin Pract 2002; 56: 53-6.
40. Evans M, Rees A. Effects of HMG-Co reductase inhibitors on skeletal muscle: are all statins the same? Drug Saf 2002; 25: 649-63.
41. Sica DA, Gehr TWB. Rhabdomyolysis and statin therapy: relevance to the elderly. Am J Geriatr Cardiol 2002; 11: 48-55.
42. Winger JM, Hornick T. Age-associated changes in the endocrine system. Nurs Clin North Am 1996; 31: 827-44.
43. Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004; 116: 408-16.
44. Nakahara K, Yada T, Kuriyama M, Osame M. Cytosolic Ca2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors. Biochem Biophys Res Commun 1994; 202: 1579-85.
45. Masters BA, Palmoski MJ, Flint OP et al. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. Toxicol Appl Pharmacol 1995; 131: 163-74.
46. Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998; 18: 84-112.
47. Lemaitre RN, Psaty BM, Heckbert SR et al. Therapy with hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults: evidence from the Cardiovascular Health Study. Arch Intern Med 2002; 162: 1395-400.
48. Maycock CAA, Muhlestein JB, Horne BD et al. Statin therapy is associated with reduced mortality across all age groups of individuals with significant coronary artery disease, including very elderly patients. Am Coll Cordiol 2002; 40: 1777-85.
49. Aronow WS, Ahn C. Incidence of new coronary events in older persons with prior myocardial infarction and serum low-density lipoprotein cholesterol ≥125 mg/dl treated with statins versus no lipid-lowering drug. Am J Cardiol 2002; 89: 67-9.
50. Sever PS, Dahlof B, Poulter NR et al. ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149-58.
51. Shepherd J, Blauw GJ, Murphy MB et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-30.
52. Deedwania P. Rationale and design of the Study Assessing Goals in the Elderly (SAGE): a comparison of aggressive versus moderate lipid-lowering therapy on myocardial ischaemia in the elderly. Atheroscler Suppl 2003; 4: 263.
53. Hobbs SD, Claridge MW, Quick CR et al. LDL cholesterol is associated with small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2003; 26: 618-22.
54. Nagashima H, Aoka Y, Sakomura Y et al. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg 2002; 36: 158-63.
55. Wierzbicki A, Sherry C. Aortic stenosis: An atherosclerotic disease? J Heart Valve Dis 1999; 8: 416-23.
56. Bellamy MF, Pellikka PA, Marich KW et al. Association of cholesterol levels, hydroxymethylglutaryl coenzyme-A reductase inhibitor treatment, and progression of aortic stenosis in the community. J Am Coll Cardiol 2002; 40: 1723-30.
57. Novaro GM, Tiong IY, Pearce GL et al. Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis. Circulation 2001; 104: 2205-9.
58. Shavelle DM, Takasu J, Budoff MJ et al. HMG CoA reductase inhibitor (statin) and aortic valve calcium. Lancet 2002; 359: 1125-6.
59. Elisaf M, Mikhailidis DP. Statins and renal function. Angiology 2002; 53: 493-502.
60. Bax L, Mali WP, Buskens E et al, STAR Study Group. The benefit of stent placement and blood pressure and lipid-lowering for the prevention of progression of renal dysfunction caused by Atherosclerotic ostial stenosis of the Renal artery. The STAR-study: rationale and study design. J Nephrol 2003; 16: 807-12.
61. Breteler MM, Claus JJ, Grobbee DE, Hofman A. Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam Study. BMJ 1994; 308: 1604-8.
62. Hofman A, Ott A, Breteler MM et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet 1997; 349: 151-4.
63. Kivipelto M, Helkala E-L, Laakso MP et al. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001; 322: 1447-51.
64. Kivipelto M, Helkala E-L, Laaskso MP et al. Elevated midlife serum cholesterol levels increase the risk of Alzheimer's disease later in life. Eur Heart J 2002; 23 (Suppl): 192.
65. Yaffe K, Barrett-Connor E, Lin F, Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 2002; 59: 378-84.
66. Jick H, Zornberg GL, Jick SS et al. Statins and the risk of dementia. Lancet 2000; 356: 1627-31.
67. Wolozin B, Kellman W, Ruosseau P et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57: 1439-43.
68. Hajjar I, Schumpert J, Hirth V et al. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol a Biol Sci Med Sci 2002; 57: M414-M8.
69. Rockwood K, Kirkland S, Hogan DB et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002; 59: 223-7.
70. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II. Eur Heart J 2001; 22: 554-72.
71. Reid FD, Cook DG, Whincup PH. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart 2002; 88: 15-9.
72. Whincup PH, Emberson JR, Lennon L et al. Low prevalence of lipid lowering heart drug use in older men with established coronary heart disease. Heart 2002; 88: 22-9.
73. Majeed A, Moser K, Maxwell R. Age, sex and practice variations in the use of statins in general practice in England and Wales. J Public Health Med 2000; 3: 275-9.
74. Williams D, Bennett K, Feely J. Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care. Br J Clin Pharmacol 2003; 5 5: 604-8.
75. Massing MW, Sueta CA, Chowdhury M et al. Lipid management among coronary artery disease patients with diabetes mellitus or advanced age. Am J Cardiol 2001; 87: 646-9.
76. DeWilde S, Carey IM, Bremner SA et al. Evolution of statin prescribing 1994-2001: a case of agism but not of sexism? Heart 2003; 89: 417-21.
77. Grover SA, Coupal L, Paquet S, Zowall H. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 1999; 159: 593-600.
78. Avorn J, Benner J, Ford I et al. Measuring the cost-effectiveness of lipid-lowering drugs in the elderly: the outcomes research and economic analysis components of the PROSPER trial. Control Clin Trials 2002; 23: 757-73.
79. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002; 288: 462-7.
80. Benner JS, Glynn RJ, Mogun H et al. Long-term persistence in use of statin therapy in elderly patients. JAMA 2002; 288: 455-61.